Closantel (Curatrem)

Closantel represents a significant advancement in the salicylanilide class of antiparasitic compounds, providing potent activity against liver flukes, blood-feeding nematodes, and certain arthropod parasites that cause substantial economic losses in livestock production worldwide. Developed in the 1970s and introduced commercially in the 1980s, closantel has become an essential tool for managing parasitic diseases in cattle, sheep, and goats, particularly in regions where fasciolosis poses ongoing challenges to animal health and productivity. The unique pharmacological properties of closantel, including its prolonged tissue persistence and selective activity against blood-feeding parasites, distinguish it from other anthelmintic classes and provide irreplaceable capabilities for specific parasitic conditions.

The mechanism of action of closantel involves uncoupling of oxidative phosphorylation in susceptible parasites, disrupting the energy metabolism essential for parasite survival and reproduction. This effect occurs through protonophoric activity in mitochondrial membranes, where closantel shuttles protons across the inner mitochondrial membrane, dissipating the electrochemical gradient required for ATP synthesis. Blood-feeding parasites are particularly susceptible because they ingest high concentrations of closantel when consuming host blood, achieving lethal drug levels in their tissues. Non-blood-feeding parasites encounter much lower drug exposure and generally remain unaffected by closantel treatment.

Available formulations of closantel include injectable solutions typically containing 5% or 10% active ingredient for subcutaneous administration, oral drenches designed for ease of mass treatment in sheep operations, and pour-on preparations that provide convenient topical application with transdermal absorption. Some products combine closantel with other anthelmintics such as ivermectin or albendazole to broaden spectrum coverage beyond the narrow range of closantel alone. The choice of formulation depends on species being treated, specific parasites targeted, farm management practices, and regulatory considerations varying by jurisdiction.

The regulatory status of closantel varies significantly between countries, with approval for cattle and sheep in many regions but limited or no approval in others, including restricted availability in the United States where alternative flukicides are more commonly employed. Where approved, closantel products carry specific labeling for liver fluke treatment and often for Haemonchus contortus control in sheep, providing clear guidance for dose, route, and withdrawal requirements. Extra-label use may be considered in jurisdictions where closantel is available but lacks specific approval for intended applications, requiring veterinary oversight and appropriate withdrawal period establishment.

Closantel's primary therapeutic application addresses liver fluke infections caused by Fasciola hepatica and Fasciola gigantica, the major trematode parasites affecting cattle, sheep, and goats in regions where intermediate snail hosts support transmission. The drug demonstrates exceptional efficacy against adult flukes residing in bile ducts, where blood-feeding behavior exposes parasites to high concentrations of protein-bound closantel circulating in the host. Treatment of established fasciolosis reduces bile duct damage, improves liver function, and eliminates the egg production that perpetuates environmental contamination. Closantel also shows significant activity against immature flukes from approximately eight weeks of age, providing earlier intervention capability than some alternative flukicides.

Control of Haemonchus contortus, the barber pole worm or large stomach worm of sheep and goats, represents another major indication for closantel treatment in small ruminant production systems. This highly pathogenic blood-feeding nematode causes severe anemia, bottle jaw, and death in heavily infected animals, with economic losses extending to reduced growth, impaired wool production, and treatment costs. The blood-feeding behavior of Haemonchus makes it uniquely susceptible to closantel among gastrointestinal nematodes, with the drug providing potent activity while sparing most non-blood-feeding species. This selective spectrum can be advantageous for refugia-based resistance management programs seeking to maintain susceptible parasite populations.

Nasal bot infections in sheep caused by Oestrus ovis larvae respond effectively to closantel treatment, providing relief from the irritation, nasal discharge, and respiratory distress associated with larval development in the nasal passages and sinuses. The blood and tissue fluid feeding of developing bot larvae exposes them to closantel concentrations sufficient for elimination. Treatment is typically administered during fall months when mature larvae are present, preventing completion of the life cycle and reducing bot populations for subsequent seasons. Clinical improvement following treatment includes decreased head shaking, sneezing, and nasal discharge as larvae are killed and expelled or absorbed.

Blowfly strike prevention in sheep represents an important application of closantel in regions where myiasis causes significant welfare and economic impacts. While not directly lethal to adult flies, closantel treatment provides prolonged protection against strike establishment by killing early larval stages that feed on wound secretions containing the drug. The extended tissue persistence of closantel supports protection lasting several weeks following treatment, reducing the frequency of application compared to topical insecticides. Combination products incorporating closantel with insect growth regulators extend the duration and scope of protection against flystrike.

Off-label applications of closantel may be considered for parasitic conditions beyond labeled indications when alternative treatments have proven inadequate or unavailable, always under veterinary supervision with appropriate attention to food safety implications. Cattle grubs (Hypoderma species), screwworm larvae, and certain other myiasis-causing flies have shown susceptibility to closantel in limited investigations. The extended withdrawal times required for closantel, particularly in cattle, must be carefully observed regardless of the indication for which treatment is administered.

Standard dosing of closantel for cattle targets liver fluke infections at 10 mg per kilogram of body weight administered as a single subcutaneous injection, typically in the anterior neck region using appropriate injection equipment and aseptic technique. This dose provides effective clearance of adult flukes and significant activity against developing immature stages from approximately eight weeks post-infection. Some protocols recommend higher doses up to 15 mg/kg when treating cattle with heavy fluke burdens or when targeting younger immature flukes, though the incremental benefit of higher doses must be weighed against extended withdrawal periods and increased treatment costs.

Sheep dosing for closantel follows similar weight-based principles, with the standard dose for liver fluke and Haemonchus contortus control ranging from 7.5 to 10 mg per kilogram depending on product formulation and target parasite. Oral drench administration is commonly preferred in sheep operations due to the ease of treating large numbers of animals through a dosing race or handling system. Injection site reactions occur more frequently in sheep than cattle, making oral dosing additionally attractive for this species. Accurate body weight estimation is critical for sheep dosing, as the combination of smaller body size and narrower safety margin compared to some other anthelmintics increases the importance of avoiding significant under- or overdosing.

Goats present particular dosing challenges for closantel due to their different drug metabolism compared to sheep, generally requiring higher doses to achieve equivalent blood concentrations and therapeutic effect. Many veterinary references recommend increasing closantel doses for goats by 1.5 to 2 times the sheep dose, translating to approximately 15 to 20 mg/kg for fluke control. The common practice of extrapolating directly from sheep labeling without dose adjustment frequently results in treatment failure in goats, frustrating producers and potentially contributing to selection for drug resistance in parasite populations exposed to subtherapeutic concentrations.

Administration technique for injectable closantel requires attention to injection site selection, needle gauge and length, and proper restraint to ensure accurate subcutaneous delivery. Injection in the anterior neck region, preferably on the side away from the jugular vein, minimizes carcass damage at processing while providing adequate subcutaneous tissue depth for drug deposition. Use of appropriately sized needles (typically 16-18 gauge, 0.5-1 inch length depending on animal size) ensures adequate delivery without excessive tissue trauma. Proper restraint in a headgate or handling system reduces the risk of needle breakage or misdirected injection during animal movement.

Treatment timing for liver fluke control with closantel depends on regional epidemiology, seasonal transmission patterns, and production system requirements. In temperate climates with distinct transmission seasons, strategic treatments in late autumn address flukes acquired during the grazing season before they mature and cause maximum liver damage. Additional treatments may be indicated in late winter or spring to eliminate flukes that survived autumn treatment or were acquired from overwintering metacercariae. Subtropical and tropical regions may require different timing based on local conditions affecting intermediate snail host populations and transmission intensity.

Withdrawal times for closantel are notably prolonged compared to many other anthelmintics, reflecting the high lipophilicity and extensive protein binding that contribute to its extended tissue persistence and therapeutic activity. Cattle withdrawal periods for meat typically range from 28 to 45 days depending on jurisdiction and product, while sheep withdrawals may extend to 28 or more days. Milk withdrawal periods are often extended or products may not be approved for use in lactating dairy animals. These withdrawal requirements represent a significant management consideration and must be observed meticulously to prevent violative residues in marketed products.

Closantel demonstrates acceptable tolerability in target species when administered at recommended doses, though the safety margin is narrower than for some other anthelmintic classes, requiring careful attention to accurate dosing. Most animals receiving appropriate closantel treatment show no observable adverse effects, continuing normal feeding, behavior, and production activities without disruption. The favorable overall safety profile supports the widespread use of closantel in livestock production despite the potential for serious toxicity with overdosing, provided that dosing calculations and administration techniques ensure delivery of appropriate amounts.

Common side effects observed with closantel treatment include transient swelling and local tissue reaction at injection sites, which may persist for several days to weeks depending on product formulation and individual animal response. Injectable closantel products can cause more pronounced injection site reactions than some other parenteral medications, occasionally resulting in firm nodules that gradually resolve over several weeks. These reactions rarely cause systemic illness but may result in carcass trimming if injection sites have not fully resolved by processing time. Selecting injection sites in areas that will be trimmed regardless reduces economic impact of persistent reactions.

Gastrointestinal disturbances following oral closantel administration are generally mild when they occur, with some animals showing reduced appetite or soft feces for one to two days post-treatment. These effects typically resolve without intervention and should not discourage appropriate use of oral closantel formulations when indicated. Salivation may occur briefly following drench administration, reflecting the bitter taste of the medication rather than systemic effect. Ensuring complete swallowing of the dose minimizes this response and ensures full therapeutic delivery.

Serious adverse effects from closantel are primarily associated with overdosing, which can produce severe and potentially fatal toxicity manifesting as blindness, weakness, and death. The narrow margin between therapeutic and toxic doses in some species, particularly sheep and goats, makes closantel overdose a genuine concern requiring careful attention to dose calculation and administration. Ocular toxicity represents the most characteristic and concerning adverse effect of closantel overdose, with affected animals developing blindness that may be permanent due to degeneration of optic nerve and retinal structures. This toxicity can occur at doses only modestly exceeding therapeutic recommendations.

Species-specific toxicities warrant consideration when treating diverse livestock populations. Sheep demonstrate the greatest sensitivity to closantel toxicity, with doses exceeding 20 mg/kg potentially causing serious adverse effects. Goats, while requiring higher doses for efficacy, also show relatively narrow safety margins when doses approach toxic thresholds. Cattle generally tolerate closantel better than small ruminants, with a wider margin between effective and toxic doses. Young animals of any species may be more susceptible to adverse effects than adults, warranting conservative dosing approaches when treating juvenile stock.

Closantel is contraindicated in animals with known hypersensitivity to salicylanilide compounds, though documented allergic reactions to this drug class in livestock are rare. Animals that have previously experienced unusual or severe reactions to closantel treatment should not receive repeated doses without veterinary evaluation and careful risk-benefit assessment. Cross-sensitivity among different salicylanilides has been reported, suggesting caution when considering alternative compounds within this class for animals that have reacted to closantel.

Use in animals intended for human consumption within the specified withdrawal periods is absolutely contraindicated, as closantel residues in meat and milk pose food safety concerns that have prompted regulatory establishment of maximum residue limits and withdrawal requirements. The extended tissue persistence of closantel makes withdrawal compliance particularly critical, as premature marketing of treated animals can result in violative residues that trigger regulatory action and compromise consumer safety. Lactating dairy animals whose milk is marketed for human consumption generally should not receive closantel, as many products carry specific prohibitions against use in dairy cattle or extend milk withdrawal periods that may be impractical for commercial dairy operations.

Severely debilitated animals, those with hepatic dysfunction, or animals suffering from conditions affecting protein metabolism may handle closantel differently than healthy individuals due to the drug's extensive protein binding and hepatic processing. While not absolutely contraindicated, treatment of such animals warrants veterinary oversight and possibly dose adjustment to account for altered pharmacokinetics. Animals with existing liver damage from severe fasciolosis may paradoxically be at increased risk from treatment, as compromised hepatic function could affect drug handling and elimination.

Concurrent use with other halogenated compounds or medications known to affect mitochondrial function should be avoided due to potential for additive toxic effects. While specific interaction studies are limited, the mechanism of closantel toxicity through disruption of oxidative phosphorylation suggests caution when combined with other compounds affecting energy metabolism. Treatment of animals recently exposed to certain phosphorus-containing compounds, including some organophosphate parasiticides, may warrant additional caution or deferral of closantel treatment.

Drug interactions involving closantel in livestock production settings require awareness of potential additive toxicity with other mitochondrial uncouplers or compounds affecting oxidative phosphorylation. Ionophore compounds including monensin, lasalocid, and salinomycin used as feed additives for coccidiosis control and growth promotion share mechanistic similarities with closantel in their effects on cellular ion gradients and energy metabolism. While specific interaction studies with closantel are limited, the theoretical basis for concern supports avoiding concurrent treatment when practical and maintaining observation for unexpected toxicity when combination is unavoidable.

Interactions with other anthelmintic compounds are generally not problematic from a safety standpoint, with closantel commonly combined or rotated with benzimidazoles, levamisole, and macrocyclic lactones as part of comprehensive parasite management programs. Indeed, commercial combination products pairing closantel with ivermectin or albendazole are available in many markets, providing broad-spectrum coverage that addresses the narrow spectrum of closantel alone. Sequential treatment with different drug classes typically presents no interaction concerns when appropriate intervals are observed between treatments.

Vaccine interactions have not been specifically investigated for closantel, though the stress and immunological consequences of acute parasitic disease rather than drug treatment are more likely to affect vaccination responses. Strategic timing of closantel treatment relative to vaccination events may consider the potential for handling stress to affect immune responses, suggesting modest separation when scheduling permits. Treatment of animals acutely ill from heavy fluke or Haemonchus burdens addresses a more significant threat to immune function than theoretical concerns about drug-vaccine interactions.

Protein binding interactions represent a theoretical concern given closantel's extensive binding to plasma proteins, primarily albumin. Other highly protein-bound drugs could potentially compete for binding sites, altering free drug concentrations of either compound. In practical livestock medicine, few situations arise where closantel would be administered concurrently with other highly protein-bound medications, making this theoretical interaction of limited clinical significance. However, awareness of this pharmacokinetic characteristic supports caution when combining closantel with other medications in unusual therapeutic situations.

Human safety precautions during closantel handling and administration include avoiding skin contact with injectable or drench formulations, as the drug can be absorbed transdermally with potential for systemic effects in handlers. Protective gloves should be worn when preparing and administering closantel products, with immediate washing of any skin contact areas. Eye protection is advisable when working with liquid formulations that could splash during measuring or administration. The characteristic ocular toxicity of closantel overdose in animals raises concerns about potential similar effects in humans following substantial exposure, warranting strict adherence to protective measures.

Food safety considerations for closantel use require meticulous attention to withdrawal periods that exceed those for most other anthelmintics. The extended tissue persistence providing therapeutic advantage also creates prolonged residue concerns requiring withdrawal periods of four weeks or longer in many jurisdictions. Producers must maintain accurate treatment records documenting product used, dose administered, date of treatment, and calculated withdrawal end date. Systems for identifying and segregating treated animals prevent inadvertent early marketing and potential violation of residue standards. Commercial operations should verify buyer requirements regarding drug withdrawal history, as some markets specify withdrawal periods exceeding regulatory minimums.

Environmental considerations include appropriate disposal of unused product, syringes, and containers in accordance with local regulations for veterinary pharmaceutical waste. Closantel residues excreted by treated animals have been investigated for potential environmental effects, with some studies documenting toxicity to certain invertebrate organisms in aquatic systems. Avoiding treatment of animals immediately before they access waterways and appropriate management of runoff from areas where treated animals are held supports environmental stewardship. The selective activity of closantel against certain organisms raises concerns about potential non-target effects that warrant continued monitoring and research.

Resistance development to closantel has been documented in both Fasciola and Haemonchus populations, with concerningly high levels reported from some geographic regions with extensive selection pressure. The narrow spectrum of closantel, limited to blood-feeding parasites, means that resistant individuals surviving treatment continue to contribute to the population without dilution from susceptible competitors as occurs with broader-spectrum drugs. Integrated resistance management incorporating refugia principles, combination treatments, and regular efficacy monitoring through fecal egg count reduction testing supports preservation of closantel efficacy.

Proper use to maintain therapeutic efficacy emphasizes accurate dosing based on current body weights rather than estimates or outdated records. The narrow safety margin of closantel makes underdosing (risking treatment failure and resistance selection) and overdosing (risking toxicity, particularly blindness) equally concerning. Calibration of dosing equipment, verification of product concentration, and careful calculation for each treatment group support appropriate dose delivery. Veterinary involvement in establishing treatment protocols and monitoring outcomes helps optimize closantel use within comprehensive parasite management programs.

Storage requirements for closantel products specify protection from light, which can degrade the active compound and reduce potency over time. Products should be stored in original containers designed to exclude light, kept in a clean, dry location away from direct sunlight or fluorescent illumination. Temperature recommendations typically specify storage between 15 and 30 degrees Celsius, with protection from freezing that could affect product integrity and cause precipitation of active ingredients in solution formulations. Extreme heat should similarly be avoided, as elevated temperatures accelerate chemical degradation processes.

Multi-dose vial handling for injectable closantel products requires aseptic technique to prevent contamination that could introduce bacteria into the product and subsequently into treated animals. Each withdrawal should employ a clean needle, with the vial septum swabbed with alcohol before penetration. Partially used vials should be dated when first opened, and manufacturer guidance regarding beyond-use dating should be followed. Any evidence of contamination, including particulate matter, color change, or unusual odor, warrants immediate disposal of the affected product. Storage of opened vials should follow label guidance, with some products requiring refrigeration after opening while others remain stable at room temperature for limited periods.

Disposal of closantel products, unused medication, and containers requires attention to both drug residue and environmental safety concerns. Unused product should not be disposed of through ordinary drainage systems or trash collection where environmental exposure or accidental contact could occur. Many jurisdictions provide pharmaceutical take-back programs or veterinary disposal services ensuring appropriate handling of unused medications. Empty containers, particularly those from concentrated injectable products, should be triple-rinsed with the rinsate used for treating animals or disposed of as pharmaceutical waste. Sharps disposal for used needles and syringes should follow established protocols to prevent injury and inappropriate environmental release.

Species-specific dosing for closantel varies significantly among the ruminant species commonly treated, with cattle generally receiving 10 mg/kg, sheep 7.5-10 mg/kg, and goats requiring elevated doses of 15-20 mg/kg to achieve equivalent therapeutic effect. These differences reflect variations in drug metabolism, tissue distribution, and protein binding among species that affect the relationship between administered dose and achieved blood concentrations. Applying sheep doses to goats, a common error, frequently results in treatment failure that frustrates producers and potentially selects for resistant parasites. Species-specific product selection, where available, simplifies appropriate dosing and reduces error risk.

Breed sensitivities within species have been occasionally reported, with anecdotal suggestions that certain sheep breeds may be more susceptible to closantel toxicity than others. While definitive breed-specific studies are limited, awareness of potential variation supports conservative dosing approaches when treating unfamiliar breeds and careful observation following initial treatment in new flock situations. Historical treatment records documenting any adverse events associated with specific breeds provide valuable guidance for future treatment decisions within individual operations.

Production type considerations influence closantel use in cattle operations, where dairy versus beef management creates different constraints and opportunities. Dairy cattle present particular challenges due to milk withdrawal requirements that may be impractical for commercial milk production, leading many dairy operations to avoid closantel entirely or restrict use to dry cows with adequate time before calving. Beef cattle operations face fewer constraints but must still observe meat withdrawal periods that affect marketing timing for animals near slaughter weight. Replacement heifer programs and stocker operations may find strategic closantel treatment valuable for fluke control without immediate market timing concerns.

Age and physiological status considerations apply to closantel use across all species. Very young animals may demonstrate different pharmacokinetics than adults, potentially affecting both efficacy and safety, though specific data for neonatal ruminants is limited. Pregnant animals have been treated with closantel without documented increased reproductive risks at label doses, though some product labels may recommend caution during late pregnancy. Heavily parasitized animals in poor body condition may have altered drug handling due to reduced protein stores affecting the extensive protein binding of closantel, potentially warranting dose adjustment or enhanced monitoring.

Alternative salicylanilide anthelmintics include oxyclozanide, niclosamide, and rafoxanide, which share the mechanism of oxidative phosphorylation uncoupling with closantel while demonstrating somewhat different spectrum and pharmacokinetic properties. Oxyclozanide provides similar liver fluke activity with possibly better tolerability but shorter duration of action requiring more frequent treatment for sustained control. Rafoxanide offers comparable Fasciola and Haemonchus coverage with extended persistence similar to closantel. Selection among salicylanilides may consider availability, cost, withdrawal requirements, and any regional variation in efficacy related to local parasite populations.

Different mechanism alternatives for liver fluke control include the benzimidazoles albendazole and triclabendazole, which disrupt microtubule function rather than energy metabolism. Triclabendazole provides unique activity against early immature flukes from one week post-infection, making it particularly valuable for acute fasciolosis treatment when young flukes are causing liver damage before reaching stages susceptible to other flukicides. Albendazole at elevated doses demonstrates flukicidal activity against adult Fasciola, though its primary registration is for nematode control. Clorsulon, a sulfonamide compound, offers another mechanism option for fluke control, sometimes combined with ivermectin for convenient broad-spectrum treatment.

Combination products containing closantel with other anthelmintic classes expand the spectrum of single treatments to address the narrow activity range of closantel alone. Closantel-ivermectin combinations provide activity against flukes, Haemonchus, and the broader nematode spectrum covered by macrocyclic lactones, plus external parasites susceptible to ivermectin. Closantel-albendazole products similarly extend spectrum while maintaining fluke and blood-feeding nematode coverage. These combinations simplify treatment protocols for operations facing diverse parasite challenges and may provide resistance management benefits through simultaneous exposure to multiple mechanisms, reducing the selective advantage of single-drug resistance.